Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28981 | 0.87 | LMNA (0.58) | LMNAHTTCCKBRALDH1A1PIN1 | |
| SCHEMBL2530533 | 0.78 | LMNA (0.58) | LMNAHTTMETAP2ALDH1A1HPGD | |
| SCHEMBL12220857 | 0.78 | LMNA (0.81) | LMNAHTTMETAP2ALDH1A1HPGD | |
| SCHEMBL5597963 | 0.76 | CCKBR (0.62) | METAP2CCKBRALDH1A1HPGDHSD17B10 | |
| SCHEMBL13484281 | 0.76 | CMA1 (0.58) | LMNAHTTMETAP2ALDH1A1 | |
| SCHEMBL13484207 | 0.75 | LMNA (0.72) | LMNAHTTMETAP2ALDH1A1HPGD | |
| SCHEMBL16479406 | 0.74 | LMNA (0.68) | LMNAHTTMETAP2ALDH1A1HPGD | |
| SCHEMBL25072652 | 0.74 | RAD52 (0.56) | HTTALDH1A1HPGDHSD17B10TP53 | |
| SCHEMBL2534878 | 0.74 | LMNA (0.86) | LMNAHTTMETAP2ALDH1A1HPGD | |
| SCHEMBL16479405 | 0.72 | LMNA (0.71) | LMNAHTTMETAP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | LMNA 3548/4885HTT 4358/4885METAP2 2446/4885 |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | LMNA 3548/4885HTT 4358/4885METAP2 2446/4885 |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | LMNA 3548/4885HTT 4358/4885METAP2 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.